Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) have been assigned an average rating of “Buy” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Eleven investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $43.44.
AAPG has been the topic of a number of research reports. Citigroup started coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research report on Thursday, October 8th. Citizens Jmp started coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective on the stock. BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, William Blair assumed coverage on shares of Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating for the company.
Read Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Trading Down 0.5%
Shares of NASDAQ:AAPG opened at $15.36 on Tuesday. The business’s 50 day moving average is $15.52 and its 200 day moving average is $19.83. Ascentage Pharma Group International has a 52-week low of $13.46 and a 52-week high of $34.50. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million during the quarter. Sell-side analysts predict that Ascentage Pharma Group International will post -2.43 EPS for the current fiscal year.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.
Recommended Stories
- Five stocks we like better than Ascentage Pharma Group International
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
